Skip to Content


Active Substance: aliskiren / amlodipine / hydrochlorothiazide
Common Name: aliskiren / amlodipine / hydrochlorothiazide
ATC Code: C09XA54
Marketing Authorisation Holder: Novartis Europharm Ltd.
Active Substance: aliskiren / amlodipine / hydrochlorothiazide
Status: Withdrawn
Authorisation Date: 2011-11-22
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Cardiovascular system

Therapeutic Indication

Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.

The marketing authorisation for Rasitrio has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.